Black Diamond Therapeutics, Inc. 宣布,其候选药物Silevertinib在针对携带EGFR非经典突变的一线非小细胞肺癌患者的2期临床试验中,取得了积极成果。这项研究结果展现了该药物在特定患者群体中的治疗潜力,为后续开发提供了关键数据支持。
Black Diamond Therapeutics, Inc. 宣布,其候选药物Silevertinib在针对携带EGFR非经典突变的一线非小细胞肺癌患者的2期临床试验中,取得了积极成果。这项研究结果展现了该药物在特定患者群体中的治疗潜力,为后续开发提供了关键数据支持。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.